Last reviewed 2026-08-25
The mitochondrial compounds have real, interesting biology and thin human outcome evidence. NAD+ precursors reliably raise measured NAD+ levels in human trials; they have not been shown to reduce fatigue or improve energy in any rigorous way. Persistent fatigue also has a long list of treatable medical causes, and those are worth excluding before spending money here.
Fatigue is one of the most common reasons people go looking for peptides, and mitochondrial dysfunction is an appealing explanation for it.
The biology is genuine: NAD+ is central to mitochondrial energy metabolism and does decline with age. The gap is between raising a measured level and changing how someone feels, and that gap has not been closed by the available human trials.
Anyone with persistent fatigue should have thyroid function, iron, B12, sleep apnoea and depression assessed first. Those are common, treatable, and far more likely to be the answer.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| NAD+ | Limited human data | Research | $200–$800 |
| MOTS-c | Animal studies only | Research | $200–$500 |
| SS-31 (Elamipretide) | Human trials, not approved for this use | FDA-approved | $500–$1200 |
Coenzyme central to mitochondrial energy production.
The catch: Human trials show precursors raise NAD+ levels. Demonstrated benefit for fatigue or energy has not followed. IV NAD+ infusions are widely sold at high cost on this unproven basis.
Mitochondrial-derived peptide linked to exercise capacity and metabolic regulation.
The catch: Exercise-mimetic findings are from mice. No human interventional data.
Targets cardiolipin in the inner mitochondrial membrane to support mitochondrial efficiency.
The catch: Real clinical trial evidence in a rare mitochondrial disease. That does not extend to ordinary fatigue.
Nothing here has been shown to improve energy or reduce fatigue in a controlled human trial. NAD+ precursors do raise NAD+ levels, which is a different claim.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
NAD+ requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
Human trials show NAD+ precursors raise measured NAD+ levels. They have not shown a reliable improvement in fatigue or subjective energy. The marketing tends to present the first finding as though it established the second.
They are among the most expensive interventions in this space and rest on the same unproven inference — that raising NAD+ improves how you feel. Before spending on them, it is worth excluding thyroid disease, anaemia, B12 deficiency, sleep apnoea and depression.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory